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Genetic Variants of the Vitamin D Receptor Gene
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Elizabeth A. Grimm5 and Qingyi Wei1
Sunlight causes DNA damage but also induces production of vitamin D whose metabolite 1,25-(OH)2D3 has
antiproliferative and pro-differentiative effects in both melanocytes and cutaneous melanoma (CM) cells
mediated through the vitamin D receptor (VDR). We hypothesized that genetic polymorphisms of VDR are
associated with risk of CM. In a hospital-based case–control study of 602 non-Hispanic white CM patients and
603 cancer-free control subjects frequency matched by age and sex, we genotyped two VDR polymorphisms
(TaqI and FokI) and assessed their association with CM risk. We found that a significantly decreased risk was
associated with VDR-TaqI Tt (adjusted odds ratio (OR), 0.70; 95% confidence interval (CI), 0.54–0.90) and Ttþ tt
(OR¼ 0.70; 95% CI, 0.55–0.89) genotypes, compared with the VDR-TaqI TT genotype, whereas an increased risk
was associated with VDR-FokI Ff genotype (OR¼ 1.32; 95% CI, 1.03–1.68), and a borderline significantly increased
risk was associated with Ffþ ff (OR¼ 1.26; 95% CI, 1.00–1.59) genotypes, compared with the VDR-FokI FF
genotype. In conclusion, genetic variants (i.e., TaqI t protective allele and FokI f risk allele) in VDR may alter
risk of CM.
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INTRODUCTION
Cutaneous melanoma (CM) is the most serious form of skin
malignancies. Its incidence has been steadily increasing for
the last 30 years (Chung et al., 2004). In 2006, there will be
an estimated 62,190 new CM cases and 7,910 deaths from
CM in the United States (Jemal et al., 2006). Therefore, CM
poses an important health issue. Although the etiology of CM
remains unclear, sunlight and genetic predisposition are
known to play important roles (Gilchrest et al., 1999;
Goldstein et al., 2001). Recently, several studies have
provided clues regarding the molecular mechanisms under-
lying such genetic susceptibility. Accumulating evidence has
indicated that genetic polymorphisms in genes involved in
cell proliferation, such as the vitamin D receptor (VDR) gene,
may contribute to the etiology of CM (Osborne and
Hutchinson, 2002; Howell, 2004).
Vitamin D metabolite 1,25-(OH)2D3 and its analogs
have strong antiproliferative and differentiation-inducing
effects mediated by VDR that is encoded by a gene (VDR)
mapped to chromosome 12q12–14 (Baker et al., 1988).
Recent studies indicated that the VDR gene has at least 62
polymorphisms in the promoter, in and around exons 2–9,
and in the 30UTR region (Uitterlinden et al., 2004; Fang et al.,
2005), of which a few have been investigated in most of
published association studies. The most studied variants
include a poly-A microsatellite in the 30 flanking region,
changes in intron 8 that generate BsmI and ApaI restriction
enzyme sites, a synonymous change at codon 352 in exon 9
that generates a TaqI restriction enzyme site, and a 50 FokI site
in exon 2 that alters the start codon (Berndt et al., 2006).
However, the linkage disequilibrium (LD) study revealed
that TaqI, BsmI, and ApaI polymorphisms were in strong
linkage disequilibrium and that the FokI polymorphism
showed very weak or no linkage to any of the other VDR
polymorphisms (Fang et al., 2005). Although the functional
significance of these variants is largely unknown, accumu-
lated evidence suggests that they may have functional
consequences, such as effects on carcinogenesis (Bikle
et al., 2005).
The VDR protein is expressed in both normal and
malignant melanocytes, and 1,25-(OH)2D3 appears to be
able to inhibit the growth of both normal and malignant
melanocytes in vitro (Ranson et al., 1988; Milde et al., 1991;
Seifert et al., 2004). Furthermore, low serum levels of
1,25(OH)2D3 were found in malignant melanoma patients
and the VDR polymorphisms were associated with both the
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occurrence and outcome of CM (Hutchinson et al., 2000).
Even though, only two relatively small studies from the same
research group have investigated the association with
melanoma (Hutchinson et al., 2000; Halsall et al., 2004).
Given the relatively strong experimental yet sparse epide-
miologic evidence, we hypothesized that the VDR poly-
morphisms are associated with risk of developing CM. As the
TaqI t allele well represents BsmI B, ApaI A, and poly-A S
alleles in LD analysis, we only determined TaqI and FokI
genotype frequencies in 602 Caucasian patients with CM
and 603 cancer-free control subjects frequency matched
by age, sex, and ethnicity, and explored the interaction
between sunlight exposure and VDR polymorphisms in
the etiology of CM.
RESULTS
Because non-Caucasian subjects represented less than 1%,
they were excluded from the analyses. As a result of
frequency matching, no statistically significant differences
in the frequency distribution of age or sex between patients
and control subjects were found. Among the cases, tumor
sites were the head and neck (14%), an upper extremity
(26%), a lower extremity (21%), the trunk (36%), and other
sites (3%). On the basis of the American Joint Committee on
Cancer T-category criteria and Breslow thickness (Balch
et al., 2001), 47% had tumors p1.0 mm (T1), 24% had
tumors 1.01–2.0 mm (T2), and 16% had tumors 42.01 mm
(T3 or T4); the rest were unclassified. Ten percent of the
tumors were at a Clark level of I (in situ), 55% at a level of II
or III, and 35% at a level of IV or V. As previously described
(Li et al., 2006), the frequencies of most classic phenotypic
traits that are known risk factors for CM were significantly
higher in cutaneous malignant melanoma patients than in
control subjects after adjustment for age and sex. Therefore,
these risk factors seemed to be involved in the etiology of CM
in this study population and were used in our later analysis of
gene–gene and gene–environment interaction.
The genotype and allele frequencies of the VDR poly-
morphisms and their associations with CM risk are presented
in Table 1. The distribution of genotypes among control
subjects was in agreement with the Hardy–Weinberg
equilibrium (P¼ 0.437 for VDR-TaqI and P¼0.784 for
VDR-FokI). The VDR-TaqI variant t allele frequency was
significantly lower among patients than among control
subjects (37.9% vs 43.0%, P¼0.012). Although it was not
statistically significantly different, the VDR-FokI variant f
allele frequency was higher among patients than control
subjects (37.4% vs 35.2%, P¼ 0.280). For the VDR-TaqI
polymorphism, the frequency distribution of the TT, Tt, and tt
genotypes between the cases and the controls was statisti-
cally significantly different (P¼0.010) (Table 1). Specifically,
the frequency of combined variant genotype (Ttþ tt) was
significantly lower in the cases than in the controls (60.0 vs
68.3%) (P¼ 0.003). For the VDR-FokI polymorphism, how-
ever, the frequency distribution of the FF, Ff, and ff genotype
frequencies was not significantly different (P¼0.064), but the
combined Ffþ ff genotype frequency was significantly higher
in the cases than in the controls (63.8 vs 58.2%) (P¼0.047).
The distributions of these VDR alleles and genotypes were
independent of tumor sites, the American Joint Committee on
Cancer T-category criteria, and Clark levels (all P40.05; data
not shown).
When the VDR-TaqI TT genotype was used as the
reference, a significantly decreased risk for CM was
associated with the Tt genotype (adjusted odds ratio (OR),
0.70; 95% confidence interval (CI), 0.54–0.90), tt genotype
(adjusted OR, 0.71; 95% CI, 0.50–0.99), and the Ttþ tt
genotype (adjusted OR, 0.70; 95% CI, 0.55–0.89) after
adjustment for age and sex (Table 1). When the VDR-FokI
FF genotype was used as the reference, a significantly
increased risk for CM was associated with the Ff genotype
(adjusted OR, 1.32; 95% CI, 1.03–1.68) and a borderline
significantly increased risk for the Ffþ ff genotype (adjusted
OR, 1.26; 95% CI, 1.00–1.59), after adjustment for age and
sex. To explore possible gene–gene and gene–environment
interactions, the VDR-TaqI genotype groups with Ttþ tt
genotypes versus groups with TT genotypes, and VDR-FokI
genotype groups with Ffþ ff genotypes versus groups with FF
genotypes were further stratified by age, sex, host character-
istics (e.g., color of skin, eyes, and hair), sun exposure history
(e.g., tanning ability, lifetime number of sunburns with
blistering and freckling in the sun as a child), Fitzpatrick’s
sun-reactive skin type, presence of moles and dysplastic nevi,
and family history of cancer. However, we did not find
evidence of any interaction between the Ttþ tt, Ffþ ff
genotypes and the measured known risk factors.
DISCUSSION
In this hospital-based, case–control study of CM, we
demonstrated that overall, the VDR TaqI Tt, tt, and Ttþ tt
genotypes were associated with a decreased risk of CM, but
the VDR FokI Ff and Ffþ ff genotypes were associated with a
significantly increased and borderline risk of CM, respec-
tively. These data suggest that the varint t allele may provide
some protection against risk of CM, whereas the variant f
allele may increase risk of CM. Although, exactly how the
VDR TaqI and FokI variants influence the risk of CM remains
unknown, these variants could be functional themselves, or
they could be in linkage disequilibrium with other functional
variants involved in the etiology of CM. Despite the lack of
related mechanistic data, several lines of evidence support
the role of the VDR gene in the etiology of CM.
The 1,25-(OH)2D3 is a well-known potent regulator of cell
growth and differentiation because of its effects on cell death,
tumor invasion, and angiogenesis (Giovannucci, 2005). The
1,25-(OH)2D3 acts by binding a corresponding intra-nuclear
receptor, VDR (Holick, 2000). The VDR TaqI and FokI
polymorphisms were found to be associated with tumor
occurrence and the behavior of different types of cancer
including CM (Hutchinson et al., 2000; Guy et al., 2004;
Berndt et al., 2006), although the results were controversial,
and, in some cases, even contradictory.
In one study reported by Hutchinson et al. (2000), the
VDR-TaqI polymorphisms were not associated with the risk
for CM in 316 CM patients and 108 control subjects, whereas
we found that the risk for CM was reduced by 30% in subjects
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having the Tt or the combined Ttþ tt genotype, and 29% in
those having the tt genotype. Interestingly, a recent study
found an association between the TaqI tt genotype and a
reduced risk for prostate cancer only in the presence of high
sun exposure in a case-only analysis (John et al., 2005).
Although we were not able to verify this finding, we did not
find any evidence of the interactions between TaqI genotypes
and all risk factors measured in this study, including history of
sunburn. One study found that the F allele-containing
genotypes were associated with a decreased risk for CM
(Hutchinson et al., 2000). Consistent with this study, we did
find that FokI FF genotype was associated with a reduced
risk for CM.
The apparent contradictions in VDR polymorphism
association studies may be due to differences in serum
vitamin D levels, population stratification, and sample sizes
included in the published studies (Valdivielso and Fernandez,
2006). The anticancer effects of vitamin D are now being
widely explored for cancer prevention, and promising results
support the role of vitamin D in reducing incidence and
mortality rates of a broad range of cancer (Giovannucci,
2005). However, like many other studies, this study, although
the largest CM case–control study to date, did not have data
on serum vitamin D levels of the study participants. In a
meta-analysis of VDR polymorphisms and risk for prostate
cancer, the t allele frequency among 1,978 Caucasians was
0.404 (Ntais et al., 2003), which is similar to the frequency of
0.430 in our 603 control subjects. In a study on the FokI
polymorphism and risk of prostate cancer, the f allele
frequencies were 0.380, among 523 Caucasian male control
subjects (Cheteri et al., 2004), which are also similar to the
frequencies of 0.352 in our 603 control subjects. The
agreement between our results and those of other studies in
genotype frequencies indicates that the bias, if any, in our
estimates of the VDR t and f allele frequencies are unlikely to
be substantial.
The VDR-TaqI variant exists as either ATC or ATT, both of
which code for isoleucine and thus may affect the stop codon
(TGA) (Gross et al., 1996). The TaqI polymorphism is located
near the 30 end of the gene, not altering the amino-acid
sequence of the VDR protein, and thus the functional
significance of this variant is unclear (Fang et al., 2005).
However, it is thought that the 30 untranslated region
sequence variants display cell type-specific effects on mRNA
stability and that it may regulate VDR gene transcription
(Uitterlinden et al., 2004). The VDR FokI consisted of a T to C
inside a start codon (ATG), and thus changes the protein size
from 427aa to 424aa. However, the shorter form of the
protein (424aa) is thought to be more active than the long
form (427aa) in terms of its transactivation activity as a
transcription factor, although it might be gene-specific and
cell type-specific (Uitterlinden et al., 2004).
However, whether the effect of the VDR variants on CM
risk is due to the variant-mediated biological events or
linkage disequilibrium with untyped disease-causing alleles is
still unknown and needs further investigation. Moreover, the
role of VDR in cancer etiology appears to be more complex
for CM than for systemic cancers. For CM, there is evidence
Table 1. Genotype and allele frequencies of the VDR polymorphisms among CM patients and control subjects and
associations with risk in non-Hispanic whites
CM patients (n=602) Control subjects (n=603)1
VDR genotype n % n % P-value2 Adjusted OR (95% CI)3 P-value4
TaqI — — — — 0.010* — —
TT 241 40.0 191 31.7 — 1.00 —
Tt 266 44.2 305 50.6 — 0.70 (0.54–0.90) 0.005
Tt 95 15.8 107 17.7 — 0.71 (0.50–0.99) 0.041
Tt+tt 361 60.0 412 68.3 0.003** 0.70 (0.55–0.89) 0.003
t allele frequency — 37.9 — 43.0 0.012*** — —
FokI — — — — 0.064* — —
FF 218 36.2 252 41.8 — 1.00 —
Ff 318 52.8 278 46.1 — 1.32 (1.03–1.68) 0.027
Ff 66 11.0 73 12.1 — 1.03 (0.71–1.51) 0.871
Ff+ff 384 63.8 351 58.2 0.047** 1.26 (1.00–1.59) 0.054
f allele frequency — 37.4 — 35.2 0.280*** — —
CI, confidence interval; CM, cutaneous melanoma; OR, odds ratio; VDR, vitamin D receptor.
1The observed genotype frequency among the control subjects was in agreement with the Hardy–Weinberg equilibrium (w2=0.603, P=0.437 for TaqI; and
w2=0.078, P=0.784 for FokI).
2Two-sided w2 test for either genotype distribution or allele frequency: *for distribution of three genotypes; **for distribution of combined genotypes; ***for
allele distribution.
3ORs were adjusted for age and sex in a logistic regression model.
4P-values were obtained in a logistic regression model adjusted by age and sex.
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of a protective effect of sunlight-induced vitamin D3 in the
skin. However, UV light from the sun not only induces
vitamin D3 in the skin but also is mutagenic by causing
DNA damage to the skin (Osborne and Hutchinson, 2002).
The outcomes of UV exposure, a double-edged sword to
the skin, appear to depend on a delicate balance between
both beneficial and harmful effects of UV light (Berwick
et al., 2005). Our data suggest that genetic variants in the
VDR gene could have an impact on this balance (Bikle et al.,
2005) and that the effect of vitamin D3 mediated by the VDR
variants is likely to alter CM risk as a result of differential
effects of sunlight exposure on the skin. Nevertheless, these
hypotheses need to be further investigated in larger,
prospective studies.
MATERIALS AND METHODS
Study subjects
Details of the study population and subject recruitment have been
described elsewhere (Li et al., 2006). Briefly, patients with newly
diagnosed and untreated CM who were referred to The University of
Texas M.D. Anderson Cancer Center between May 1994 and
September 2004 were recruited. The tumors of all patients with CM
recruited for this study were histologically classified according to the
2002 American Joint Committee on Cancer ‘‘melanoma staging
system’’ (Balch et al., 2001). As previously described (Li et al., 2006),
cancer-free control subjects were recruited during the same period
from cancer-free visitors to M.D. Anderson who were not seeking
medical care but instead accompanied patients to our outpatient
clinics and were frequency matched to patients with CM by age
(75 years), sex, and ethnicity and not blood related to the patients.
After we obtained their informed consent, we interviewed in person
each eligible patient with CM and each control subject to obtain
data on their age, sex, ethnicity, host characteristics (e.g., colors of
skin, eyes, and hair), history of sun exposure (e.g., tanning ability,
number of sunburns with blistering in their lifetime, and freckling in
the sun as a child), and Fitzpatrick’s sun-reactive skin type
(Fitzpatrick, 1998). However, we did not collect any direct sun
exposure information. For the patients, the dysplastic nevi were
diagnosed by the dermatologists, whereas for the controls, the
dysplastic nevi were self-reported. At the end of the interview, a
sample of blood (30 ml) was drawn from each patient and control
subject and collected in a heparinized tube. The study was
conducted according to the Declaration of Helsinki Principles, and
the study protocol was approved by the Institutional Review Board
of M.D. Anderson.
Genotyping
A leukocyte cell pellet was obtained from the buffy coat by
centrifugation of 1 ml of whole blood. The cell pellet was used for
genomic DNA extraction using the Qiagen DNA Blood Mini Kit
(Valencia, CA). DNA purity and concentration were determined by
spectrophotometric measurement of absorbance at 260 and 280 nm.
The PCR-restriction fragment length polymorphism method was used
to amplify the fragments of the VDR gene that contained the sites of
TaqI (Taylor et al., 1996) and FokI (Hutchinson et al., 2000), as
described previously. The genotyping assays for approximately 15%
of the samples were repeated, and the results were 100%
concordant.
Statistical analysis
The w2 test was used to evaluate the differences in the frequency
distributions of selected demographic variables, known risk factors,
and each allele and genotype of the VDR polymorphisms between
patients with CM and control subjects. Given that skin color was
self-assessed on the screening questionnaire on a scale of 1 (light) to
10 (dark), we categorized skin color values of 1 or 2 as fair skin, 3 or
4 as brown skin, and 5–10 as dark skin to obtain similar numbers of
observations in each stratum and thus facilitate a further stratification
analysis. Univariate and multivariate unconditional logistic regres-
sion analyses were used to obtain the crude and adjusted ORs for the
risk of CM and the 95% CIs. Multivariate adjustments were made,
where appropriate, for age and sex. The genotype data were further
stratified by age, sex, host characteristics (e.g., color of skin, eyes,
and hair), sun exposure history (e.g., tanning ability, lifetime number
of sunburns with blistering, and freckling in the sun as a child),
Fitzpatrick’s sun-reactive skin type, presence of moles and dysplastic
nevi, and family history of cancer. To facilitate the assessment of the
potential interaction of the VDR polymorphisms on CM risk, we
dichotomized VDR genotype variables based on the assumption of a
given genetic model (i.e., recessive, co-dominant, and dominant).
ORs, 95% CIs, and P-values for interactions and trend tests were
obtained from multivariate logistic regression models, in which an
interactive term was created as the product of two dichotomized
variables with adjustment for their main effects; statistical signifi-
cance was established at a P-value of 0.05. All tests were two-sided
for statistical significance and conducted by using SAS software
(version 8.2; SAS Institute, Cary, NC).
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